Kyowa Hakko Kirin Expands Into Japan’s Diabetes Market With DPP-4 Onglyza Launch
This article was originally published in PharmAsia News
Executive Summary
Kyowa Hakko Kirin launched Onglyza (saxagliptin), Japan’s seventh DPP-4 (dipeptidyl peptidase-4) inhibitor July 9.